Delix Therapeutics

Delix Therapeutics is an American biotech company based in Boston, Massachusetts.[1] The company develops novel neuroplasticity-promoting therapeutics for central nervous system (CNS) diseases such as depression and post-traumatic stress disorder (PTSD).[2] It was co-founded in 2019 by David E. Olson and Nick Haft.[3]

Delix Therapeutics, Inc. ("Delix")
TypePrivate
Industry
Founded2019
HeadquartersBoston, Massachusetts
Key people
Mark Rus (Chief Executive Officer)
Websitehttps://www.delixtherapeutics.com

Company History

The company was founded to develop novel psychoplastogens to better treat mental health disorders at scale. David E. Olson founded the company following his discovery that psychedelics are highly potent neuroplasticity-promoting compounds.[2] In September 2021, Delix secured a Series A financing round to continue their work focused on psychoplastogens and neuroplasticity therapeutics.[4] Also in Fall of 2021, Delix joined the National Institute on Drug Abuse industry partnering program to screen psychoplastogens in models of substance use disorder.[2] In 2021, the company expanded the leadership team, adding a new CEO,[5] CSO,[1] and CMO[1]

Product Candidates

To date, the company has synthesized over 1000 novel psychoplastogens.[6] Many of these small molecule compounds are analogs of known psychedelics such as ibogaine and 5-MeO-DMT.[7] Delix focuses on the development of non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.[8] Their compounds have been engineered to lack cardiotoxicity and psychostimulant properties characteristic of other first-generation psychoplastogens.[9] Two of the company’s known compounds are tabernanthalog and AAZ-A-154.[10] Delix has licensed these compounds from UC Davis.[11]

See also

References
  1. LaHucik, Kyle (2021-09-27). "Delix raises $70M to test psychedelic analogs for treating brain disorders in clinical trials next year". Fierce Biotech. Retrieved 2022-06-08.
  2. Yakowicz, Will. "Delix Therapeutics Pursues A Psychedelic-Inspired Medicine Without The Trip". Forbes. Retrieved 2022-05-18.
  3. "Harnessing Psychedelics for Healing". Comstock's magazine. Retrieved 2022-06-08.
  4. Salarizadeh, Cynthia (2022-03-11). "How Capital Markets Are Fueling Psychedelic Medicine Growth". Rolling Stone. Retrieved 2022-06-08.
  5. "Shire neuro head lands at Delix Therapeutics as CEO". FierceBiotech. 18 March 2021. Retrieved 2021-08-27.
  6. Yakowicz, Will. "U.S. Government Will Test Ibogaine Derivative As An Addiction Treatment". Forbes. Retrieved 2022-06-08.
  7. Andy Extance2020-12-17T14:30:00+00:00. "Chemists tame shamanic addiction treatment". Chemistry World. Retrieved 2022-06-08.
  8. "A new psychedelics player emerges to treat mental health disorders — minus the hallucinogenic effects". Endpoints News. Retrieved 2022-06-07.
  9. scientificinquirer (2022-03-14). "Industry Matters: Delix Therapeutics is taking Next-Gen psychedelics out of the lab and into the clinic". Scientific Inquirer. Retrieved 2022-06-07.
  10. "Can we take the high out of psychedelics?". Wired UK. ISSN 1357-0978. Retrieved 2022-10-12.
  11. Peters, Jamie; Olson, David E (January 2021). "Engineering Safer Psychedelics for Treating Addiction". Neuroscience Insights. 16: 263310552110338. doi:10.1177/26331055211033847. ISSN 2633-1055. PMC 8295933. PMID 34350400.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.